Clinical Trials Logo

Clinical Trial Summary

Background:

- Blepharospasm is caused by excessive contraction of the muscles that close the eye. One treatment is botulinum neurotoxin (BoNT), which works by weakening those muscles. Like BoNT, acetyl hexapeptide-8 (AH-8) works to weaken the muscles, but is available as a skin cream. AH-8 is the active ingredient in a number of cosmetic creams used to treat wrinkles. Researchers thought that AH-8 cream could be used to treat blepharospasm, but the original dose studied was not very effective. They want to try a higher dose of AH-8 in a cream to see if it can be a more effective treatment.

Objectives:

- To see if AH-8 cream can improve the symptoms of blepharospasm.

Eligibility:

- Individuals at least 18 years of age who have blepharospasm that is severe enough to require treatment.

Design:

- This study will involve up to eight study visits.

- Participants will be screened with a physical exam and medical history. They will answer questions about their symptoms. They will also have a blink test to see how severe the blepharospasm is. At this visit, participants will receive one of three types of cream. One cream will have a low dose of AH-8, one will have a higher dose of AH-8, and the other will be a placebo (no AH-8).

- One month later, participants will have a followup visit, with tests similar to the first visit. They will also receive more of the cream.

- One month later, participants will have another visit with the same tests. They will be videotaped at this visit to study their facial movements. Those who have responded to the treatment will continue to use the cream. Those who have not responded will be offered the chance to have BoNT injections, and will stop taking the cream.

- One month later, participants who had BoNT injections will have a final visit to check for possible side effects. Those who continued to take the cream will continue on the study.

- The fifth and sixth visits will involve the same tests as before. At the seventh visit, remaining participants will be offered the chance to have BoNT injections, and will stop taking the cream.

- The final visit will check for any side effects from the cream or the injections.


Clinical Trial Description

OBJECTIVE:

Test the efficacy of topical AH-8 in blepharospasm treatment.

DESIGN:

This is a randomized, double blind, placebo-controlled study, phase II single center clinical trial. Patients with primary blepharospasm at least 4 months off BoNT therapy with no benefit from last BoNT injection by history and self assesment will be included. We will use 3 study arms placebo and 2 different doses (as concentrations of the AH-8 active substance in the topical preparation). An extension phase is planned after the initial phase.

The patients will have a baseline screening visit, including measurement of the outcome variables, then begin the study intervention. They will have 2 subsequent visits at month 1 and month 2. After this visit, the patients who do not have significant benefit and wish to have an alternative therapy (GROUP 1) will receive BoNT injections according to best practice standards. These patients will then be assessed 1 month later (peak effect of BoNT therapy) and the effect will be compared with the AH-8 effect. The patients who have significant benefit (GROUP 2) will continue therapy for another 4 months (total of 6 months), and will have another assessment at that point. Afterwards the patients will be offered BoNT injections according to best practice standards, similar to Group 1 above, and another assessment will be made one month later (month 7) to compare the effects with AH-8 effects.

OUTCOME MEASURES:

Primary outcome variable: the Jankovic Blepharospasm Rating Scale at month 2.

Secondary outcome variables:

- the Jankovic Blepharospasm Rating Scale at month 1

- the Blepharospasm Disability Scale at month 1

- the Blepharospasm Disability Scale at month 2

- the difference in JBRS at month 3 time point (after BoNT injection) in patients receiving BoNT

- JBRS score at 6 months for patients not receiving BoNT at month 2 (Group 2)

- the difference in JBRS between month 6 and month 7 time point (after BoNT injection) in Group 2 patients

- Blink reflex measures at month 2

Non-parametric comparison (Wilcoxon Mann-Whitney test) of the primary and secondary variables before and after the intervention will be used for statistical analysis. Additional multivariate analysis will explore the influence of other factors (age, gender, disease duration).

Interventions and Duration

Twice daily application of active substance or placebo. Two active substance concentrations, 0.025% and 0.05% AH-8 will be used.

Each subject will be in the study a total of at least 3 months, followed by additional up to 4 months in the second phase for the group 2 patients.

Sample Size and Population

There will be 8 patients per arm, for a total study population of 24. The power calculation for a power of 80%, for a 2-tailed alpha of 0.05, to be able to detect a change of 2 points on the JBRS requires 8 patients per arm. This calculation was based on independent calculation for each dose of the active agent against placebo.

The subjects included will be patients with primary blepharospasm, not currently treated with BoNT (de novo diagnosed patients), but who subjectively express a wish for treatment intervention, with at least one year history from symptom onset, without perceived active change in symptoms by history. Patients with blepharospasm as part of a generalized dystonia or due to a different neurologic condition will be excluded.

Randomization and blinding to be performed by the NIH research pharmacy. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01750346
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Contact
Status Terminated
Phase Phase 2
Start date November 2012
Completion date May 2015

See also
  Status Clinical Trial Phase
Completed NCT04692285 - Electrophysiological and Neuroimaging Correlates of the Effect of Zolpidem in Patients With Focal Dystonia Phase 1
Completed NCT00505323 - Motor and Premotor Cortex Stimulation for Treatment of Secondary Focal Dystonia With Striato Palliadal Lesion : Evaluation of Safety and Effectiveness Phase 1
Terminated NCT03206112 - Loss of Depotentiation in Focal Dystonia
Completed NCT00025701 - EEG and EMG Studies of Hand Dystonia N/A
Completed NCT02334683 - Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatment of Limb Spasticity and Focal Dystonia N/A
Completed NCT03797638 - Characterization of Manual Dexterity by Finger Force Manipuladum (FFM) in Patients With Writer's Cramp and in Control Subjects N/A
Completed NCT01738581 - rTMS and Retraining in Focal Hand Dystonia Phase 1/Phase 2
Terminated NCT02106936 - Depotentiation in People With Focal Hand Dystonia N/A
Completed NCT00310414 - fMRI Studies of Task Specificity in Focal Hand Dystonia N/A
Completed NCT00309010 - Neurophysiology of Task-Specificity of Focal Hand Dystonia N/A
Completed NCT03471923 - Non-Motor Features of Cervical Dystonia (CD)
Completed NCT00306865 - Brain Changes in Patients With Focal Hand Dystonia N/A
Completed NCT00411255 - Brain Stimulation to Treat Blepharospasm or Meige Syndrome Phase 2
Terminated NCT00487383 - Brain Changes in Blepharospasm
Recruiting NCT05095740 - Effects of Neuromodulation in Laryngeal Dystonia N/A
Completed NCT00713414 - Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia
Completed NCT00942851 - A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm Phase 1/Phase 2
Completed NCT00118586 - Neuropathology of Spasmodic Dysphonia
Completed NCT02326818 - Comparison of Electrophysiologic and Ultrasound Guidance for Onabotulinum Toxin A Injections in Focal Upper Extremity Dystonia and Spasticity Phase 3
Active, not recruiting NCT02911103 - Deep Brain Stimulation Surgery for Focal Hand Dystonia Phase 1/Phase 2